Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
The purpose of this study was to evaluate the efficacy and toxicity of single-agent paclitaxel given weekly to patients with relapsed and refractory small cell lung cancer (SCLC). Patients were treated with 80 mg/m2 paclitaxel administered weekly for 1 h for 6 weeks in an 8-week cycle. Twenty-two patients were enrolled, 21 of whom were eligible. The patient characteristics included: 20 males, 1...
متن کاملWeekly cetuximab and gemcitabine plus cisplatin as salvage therapy for unresectable non-small cell lung cancer.
after 4 months of treatment (fig. 1 and 2), and was evaluated as resectable. With the patient’s permission, a left upper lobectomy (LUL) with superior segmentectomy via left thoracotomy was performed on 19 February 2008, and the pathological diagnosis was mucoepidermoid carcinoma stage T2N1. Further adjuvant chemotherapy with the same regimen was given for another 3 months. Presently in March 2...
متن کاملCarboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.
BACKGROUND Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. PATIENTS AND METHODS Fifteen advanced NSCLC patients with ILD that was detected on the chest X-rays were enrolled in this study. Carboplatin plus paclitaxel was ...
متن کاملPhase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
LESSONS LEARNED Weekly nanoparticle albumin-bound-paclitaxel (75 mg/m2) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non-small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity.This modified regimen offers potential for the treatment of elderly patients. BACKGROUND ...
متن کاملWeekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
BACKGROUND Weekly administration of irinotecan plus cisplatin was evaluated for untreated patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Sixty mg/m(2) of irinotecan plus 30 mg/m(2) of cisplatin were administered on days 1, 8 and 15 every 4 weeks. Patients with no evidence of disease progression were treated with at least two cycles (8 weeks). Of the 39 patients, 29 wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2019
ISSN: 0923-7534
DOI: 10.1093/annonc/mdz437.047